Integrated Pharmacokinetic and Drug–Drug Interaction Analysis Linking Exposure Variability to Clinical Outcomes

Abstract

efficacy and safety, particularly in complex pharmacotherapy involving multiple agents. The present study aimed to develop an integrated analytical framework linking pharmacokinetics, interaction mechanisms, and clinical safety outcomes to support therapeutic optimization. A comprehensive multi-domain dataset encompassing pharmacokinetic parameters, drug–drug interaction profiles, toxicity records, and adverse event data was systematically analyzed. Pharmacokinetic variability was assessed using key exposure metrics, including maximum plasma concentration, area under the curve, and elimination half-life. Interaction patterns were evaluated through enzyme- and transporter-mediated mechanisms, with particular emphasis on cytochrome P450 systems. Integrated analyses revealed that compounds with higher interaction burden exhibited increased variability in exposure parameters and a greater frequency of adverse events. Exposure–toxicity relationships demonstrated that elevated systemic exposure was associated with increased safety risk. Furthermore, discontinuation-related adverse outcomes were identified as the most clinically relevant indicators of therapeutic failure.These findings highlight the importance of integrating pharmacokinetic and interaction data to improve prediction of clinical outcomes. The study provides a mechanistic and translational framework for optimizing dosing strategies, minimizing adverse effects, and enhancing therapeutic effectiveness in clinical practice.